All companies
Zimmer Biomet logo

What smart money is saying about Zimmer BiometUnited States flag

ZBH · Healthcare · Medical - Devices · Market cap $17.84B

1 fund in our archive has pitched Zimmer Biomet — most recently Harris Oakmark US Large Value Strategy in June 2025.

Company profile

Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates in the musculoskeletal healthcare business in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company designs, manufactures, and markets orthopaedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; spine products comprising medical devices and surgical instruments; and face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest toss facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest. It also offers dental products that include dental reconstructive implants, and dental prosthetic and regenerative products, as well as robotic, surgical and bone cement products. The company's products and solutions are used to treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues. It serves orthopedic surgeons, neurosurgeons, oral surgeons, dentists, hospitals, stocking distributors, healthcare dealers, and other specialists, as well as agents, healthcare purchasing organizations, or buying groups. The company was formerly known as Zimmer Holdings, Inc. and changed its name to Zimmer Biomet Holdings, Inc. in June 2015. Zimmer Biomet Holdings, Inc. was founded in 1927 and is headquartered in Warsaw, Indiana.

Get an email when a fund writes about it

Summarize with Warren AI
0
Reported positions
0
Bought
0
Sold
2
Letters

Also mentioned · 1

These funds discuss Zimmer Biomet — as a competitor, benchmark or comparable — without disclosing a position in it.

  • MentionedLong Cast Advisers Small- & Micro-Cap Concentrated Strategy
    June 2026
    Zimmer’s purchase of Monogram last year included “contingent valuation rights” (CVRs) that pay out $3.41 / share in each year from 2028 to 2030 that mBos gross revenues exceed certain hurdles.
    Read the letterZimmer Biomet

Fund coverage · 1 thesis

  • Harris Oakmark US Large Value Strategy
    June 2025

    Zimmer Biomet is a leading orthopedic medical device company poised for growth due to favorable market trends and operational improvements that are currently undervalued.

    Read the full thesis

Read every full thesis on Zimmer Biomet

Unlock all 1 thesis — the full reasoning behind what funds are buying, plus unlimited access to the entire archive.

View plans
Share this ledger